Suppr超能文献

含顺铂与不含顺铂的辅助化疗用于卵巢癌。二次剖腹探查术后结果。

Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.

作者信息

Schneider J, Martin M, Erasun F, Matia J C, Rodriguez-Escudero F J

机构信息

Department of Gynecology, University Clinic of Bilbao (Hospital de Cruces), Spain.

出版信息

Oncology. 1990;47(2):109-11. doi: 10.1159/000226799.

Abstract

In 1980, second-look laparotomy was introduced simultaneously into the treatment regimen for ovarian carcinoma at the two main referral centers of northern Spain. First-line chemotherapy after initial surgery was, however, different at both hospitals. At one of them (Bilbao), a combination involving the use of cisplatin was employed (cyclophosphamide 600 mg/m2, Adriamycin 45 mg/m2, and cisplatin 80 mg/m2 i.v. on day 1), whereas the patients of the other hospital were treated mainly with single-agent chemotherapy (melphalan 0.2 mg/kg p.o. on days 1-5) and never with a cisplatin combination as first-line therapy in any case. In all, 92 patients (42 stage I, 14 stage II, 33 stage III, and 3 stage IV) could be treated during the study period with optimal surgery (complete tumor excision or largest residual tumor less than 2 cm in diameter). This was followed by adjuvant chemotherapy for 12-18 months in all cases, except for 18 patients with a stage Ia borderline or G1 tumor. The latter were merely kept under observation until their second-look laparotomy after 1 year of negative follow-up. All of the 74 patients who received adjuvant chemotherapy, of whom 36 with cisplatin and 38 without, were clinically disease free after at least twelve courses of treatment and had a second-look laparotomy performed. This was positive in 33.3% of the cases after cisplatin-containing therapy and in 26.3% of the cases after cisplatin-free therapy. This difference is not statistically significant. The mean follow-up period after negative second-look was 34 months. The long-term results of both patient groups were comparable as far as rate of positive second-look laparotomies and survival rate, overall and stage for stage are concerned. The use of cisplatin did not result in any significant therapeutic improvement. It was uniformly bad tolerated by the patients and carried higher cost, since all patients had to be hospitalized for treatment.

摘要

1980年,二次剖腹探查术同时被引入西班牙北部两个主要转诊中心的卵巢癌治疗方案中。然而,两家医院初次手术后的一线化疗方案有所不同。其中一家医院(毕尔巴鄂)采用了含顺铂的联合化疗方案(环磷酰胺600mg/m²、阿霉素45mg/m²,顺铂80mg/m²静脉滴注,第1天),而另一家医院的患者主要接受单药化疗(美法仑0.2mg/kg口服,第1 - 5天),在任何情况下都从未将含顺铂的联合化疗作为一线治疗方案。在研究期间,共有92例患者(42例I期、14例II期、33例III期和3例IV期)接受了最佳手术(完整肿瘤切除或最大残留肿瘤直径小于2cm)。除18例Ia期交界性或G1期肿瘤患者外,所有患者均接受了12 - 18个月的辅助化疗。后者仅在随访1年呈阴性后接受观察,直至二次剖腹探查术。接受辅助化疗的74例患者,其中36例接受含顺铂化疗,38例未接受,在至少接受十二个疗程治疗后临床无疾病,并进行了二次剖腹探查术。含顺铂治疗后,33.3%的病例二次剖腹探查术结果为阳性;无顺铂治疗后,26.3%的病例结果为阳性。这种差异无统计学意义。二次剖腹探查术结果为阴性后的平均随访期为34个月。就二次剖腹探查术阳性率和生存率而言,两个患者组的长期结果在总体和各分期方面具有可比性。使用顺铂并未带来任何显著的治疗改善。患者对其耐受性普遍较差,且成本更高,因为所有患者都必须住院治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验